Streetbeat News

Stock Prices

HLIT

Harmonic (NASDAQ:HLIT) reported Q2 2024 adjusted EPS of $0.08, beating the $0.04 estimate. Sales were $138.740M, surpassing the $133.666M estimate. However, both EPS and sales decreased compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:19 pm

CVRX

CVRx (NASDAQ:CVRX) reported Q2 2024 GAAP EPS of $(0.65), missing the $(0.53) estimate, but sales of $11.807M beat the $11.787M estimate. EPS decreased by 16.07% YoY, while sales increased by 24.28% YoY.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:18 pm

WWD

Woodward (NASDAQ:WWD) reported Q3 2024 GAAP EPS of $1.63, beating the analyst consensus estimate of $1.46 by 11.64%.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:17 pm

NEO

NeoGenomics (NASDAQ:NEO) reported Q2 2024 adjusted EPS of $0.03, beating the $0.00 estimate. Sales were $164.502M, surpassing the $161.847M estimate. This marks a significant improvement from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:16 pm

FFIV

F5 has raised its FY24 earnings growth expectations, now anticipating approximately 12% non-GAAP EPS growth, up from the previous outlook of 7% to 9%.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:16 pm

HOLX

Hologic shares are trading lower after the company issued soft guidance.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:14 pm

SAFE

Safehold (NYSE:SAFE) reported Q2 earnings of $0.41 per share, beating the $0.36 estimate and showing a 17.14% increase from last year. Sales were $89.89M, surpassing the $88.19M estimate and marking a 4.94% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:14 pm

WELL

Welltower has raised its FY24 net income guidance to $1.52-$1.60 per share and its normalized FFO guidance to $4.13-$4.21 per share. The company expects significant growth in Same Store NOI, particularly in Seniors Housing Operating. General and administrative expenses are anticipated to be $205-$211 million, with stock-based compensation at $40 million. The company also plans to fund $328 million in development and expects $643 million in disposition proceeds over the next twelve months.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:13 pm

CORT

Corcept Therapeutics has raised its 2024 revenue guidance from $620M–$650M to $640M–$670M, surpassing the estimated $632.15M.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:13 pm

SFM

Sprouts Farmers Market shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 earnings guidance above estimates.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:12 pm